Compare UEC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEC | IBRX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 7.5B |
| IPO Year | 2008 | 2015 |
| Metric | UEC | IBRX |
|---|---|---|
| Price | $13.05 | $7.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $18.95 | $12.57 |
| AVG Volume (30 Days) | 8.7M | ★ 11.9M |
| Earning Date | 06-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | $66,837,000.00 | ★ $113,288,000.00 |
| Revenue This Year | N/A | $88.59 |
| Revenue Next Year | $220.11 | $131.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29737.95 | 668.31 |
| 52 Week Low | $5.63 | $1.95 |
| 52 Week High | $20.34 | $12.43 |
| Indicator | UEC | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 43.25 |
| Support Level | $11.86 | $6.64 |
| Resistance Level | $14.64 | $8.51 |
| Average True Range (ATR) | 1.04 | 0.60 |
| MACD | -0.30 | -0.05 |
| Stochastic Oscillator | 24.46 | 3.90 |
Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.